Similar articles

• Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

  Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. Wallace BD, et al. Science. 2010 Nov 5;330(6005):831-5. doi: 10.1126/science.1191175. Science. 2010. PMID: 21051639 Free PMC article.
• Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

  Ahmad S, Hughes MA, Yeh LA, Scott JE. Ahmad S, et al. J Biomol Screen. 2012 Aug;17(7):957-65. doi: 10.1177/1087057112444927. Epub 2012 Apr 24. J Biomol Screen. 2012. PMID: 22535688 Free PMC article.
• Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.

  Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. Takasuna K, et al. Cancer Chemother Pharmacol. 1998;42(4):280-6. doi: 10.1007/s002800050818. Cancer Chemother Pharmacol. 1998. PMID: 9744772
• New approaches to prevent intestinal toxicity of irinotecan-based regimens.

  Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M. Alimonti A, et al. Cancer Treat Rev. 2004 Oct;30(6):555-62. doi: 10.1016/j.ctrv.2004.05.002. Cancer Treat Rev. 2004. PMID: 15325035 Review.
• Metabolism of CPT-11. Impact on activity.

  Rivory LP. Rivory LP. Ann N Y Acad Sci. 2000;922:205-15. doi: 10.1111/j.1749-6632.2000.tb07039.x. Ann N Y Acad Sci. 2000. PMID: 11193896 Review.